Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.37 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | UHRF1 | Q96T88 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12226039 | 0.80 | LOXL2 (0.44) | HPGDCYP1A2CYP2C9CYP2C19HIF1A | |
| Trifluoroacetic Acid SCHEMBL20560866 | 0.76 | PRSS1 (0.51) | PRSS1TPSAB1L3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL20560863 | 0.76 | PRSS1 (0.51) | PRSS1TPSAB1L3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL20560902 | 0.74 | PRSS1 (0.49) | PRSS1TPSAB1 | |
| Trifluoroacetic Acid SCHEMBL20561386 | 0.74 | PRSS1 (0.51) | PRSS1TPSAB1NPC1RAB9ASMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL20561389 | 0.74 | PRSS1 (0.51) | PRSS1TPSAB1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5635112 | 0.73 | CYP2C9 (0.46) | HPGDCYP1A2CYP2C9CYP2C19HIF1A | |
| SCHEMBL5047017 | 0.73 | L3MBTL1 (0.44) | HPGDALOX5NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29732021 | 0.73 | L3MBTL1 (0.44) | HPGDALOX5NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8305596 | 0.73 | L3MBTL1 (0.44) | HPGDALOX5NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511039-B2 | β-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins | MYRIAD GENETICS, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-20060293372-A1 | Beta-sheet mimetics and methods relating to the use thereof | MYRIAD GENETICS, INC. (US) | 2006-12-28 | — | — | US | disclosed |
| US-20060276408-A1 | Beta-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins | MYRIAD GENETICS, INCORPORATED (US) | 2006-12-07 | — | — | US | disclosed |
| US-7125872-B2 | β-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins | MYRIAD GENETICS, INC. (US) | 2006-10-24 | — | — | US | disclosed |
| EP-1661566-A2 | Use of beta-sheet mimetics as protease and kinase inhibitors and as inhibitors of transcription factors | MYRIAD GENETICS, INC. (US) | 2006-05-31 | — | — | EP | disclosed |
| EP-0915700-B1 | USE OF BETA-SHEET MIMETICS AS PROTEASE AND KINASE INHIBITORS AND AS INHIBITORS OF TRANSCRIPTION FACTORS | MYRIAD GENETICS INC (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20040230035-A1 | Beta-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins | MYRIAD GENETICS, INC. (US) | 2004-11-18 | — | — | US | disclosed |
| US-6699869-B1 | PROTEASE INHIBITORS, ANTICOAGULANT | MYRIAD GENETICS INC. | 2004-03-02 | — | — | US | disclosed |
| US-20030191109-A1 | Beta-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins | KAHN MICHAEL (US) | 2003-10-09 | — | — | US | disclosed |
| US-6586426-B1 | Pyrrolizine derivatives; thrombin, elastase, and factor X inhibitors | MOLECUMETICS LTD. | 2003-07-01 | — | — | US | disclosed |
| EP-0815123-B1 | BETA-SHEET MIMETICS AND USE THEREOF AS PROTEASE INHIBITORS | MOLECUMETICS LTD (US) | 2001-10-04 | — | — | EP | disclosed |
| US-6245764-B1 | PROTEASE INHIBITORS; ANTICANCER AGENTS; IMMUNOLOGY CONTROLLERS; ANTIINFLAMMATORY AGENTS | MOLECUMETICS LTD. | 2001-06-12 | — | — | US | disclosed |
| US-6117896-A | Methods for regulating transcription factors | MOLECUMETICS LTD. (US) | 2000-09-12 | — | — | US | disclosed |
| US-6020331-A | β-sheet mimetics and use thereof as protease inhibitors | MOLECUMETICS, LTD. (US) | 2000-02-01 | — | — | US | disclosed |
| EP-0915700-A1 | USE OF BETA-SHEET MIMETICS AS PROTEASE AND KINASE INHIBITORS AND AS INHIBITORS OF TRANSCRIPTION FACTORS | MOLECUMETICS, LTD. (US) | 1999-05-19 | — | — | EP | disclosed |
| WO-1998005333-A1 | USE OF BETA-SHEET MIMETICS AS PROTEASE AND KINASE INHIBITORS AND AS INHIBITORS OF TRANSCRIPTION FACTORS | MOLECUMETICS LTD. (US) | 1998-02-12 | — | — | WO | disclosed |
| EP-0817642-A1 | $g(b)-SHEET MIMETICS AND USE THEREOF AS INHIBITORS OF BIOLOGICALLY ACTIVE PEPTIDES OR PROTEINS | MOLECUMETICS, LTD. (US) | 1998-01-14 | — | — | EP | disclosed |
| EP-0815123-A1 | $g(b)-SHEET MIMETICS AND USE THEREOF AS PROTEASE INHIBITORS | MOLECUMETICS, LTD. (US) | 1998-01-07 | — | — | EP | disclosed |
| WO-1996030035-A1 | β-SHEET MIMETICS AND USE THEREOF AS INHIBITORS OF BIOLOGICALLY ACTIVE PEPTIDES OR PROTEINS | MOLECUMETICS LTD. (US) | 1996-10-03 | — | — | WO | disclosed |
| WO-1996030396-A1 | β-SHEET MIMETICS AND USE THEREOF AS PROTEASE INHIBITORS | MOLECUMETICS LTD. (US) | 1996-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293372-A1 | Beta-sheet mimetics and methods relating to the use thereof | SERBP1, PACSIN2, HGFAC | HPGD 3963/4885CYP1A2 4861/4885CYP2C9 4880/4885 |
| US-20030191109-A1 | Beta-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins | MICA, BMX, CD74 | HPGD 4540/4885CYP1A2 4806/4885CYP2C9 4680/4885 |
| US-20060276408-A1 | Beta-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins | SERPINB1, SERPINE1, SERPINA2 | HPGD 2295/4885CYP1A2 4448/4885CYP2C9 4515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.